Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.

Havunen R, Santos JM, Sorsa S, Rantapero T, Lumen D, Siurala M, Airaksinen AJ, Cervera-Carrascon V, Tähtinen S, Kanerva A, Hemminki A.

Mol Ther Oncolytics. 2018 Nov 6;11:109-121. doi: 10.1016/j.omto.2018.10.005. eCollection 2018 Dec 21.

2.

Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors.

Feola S, Capasso C, Fusciello M, Martins B, Tähtinen S, Medeot M, Carpi S, Frascaro F, Ylosmäki E, Peltonen K, Pastore L, Cerullo V.

Oncoimmunology. 2018 May 7;7(8):e1457596. doi: 10.1080/2162402X.2018.1457596. eCollection 2018.

3.

TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.

Cervera-Carrascon V, Siurala M, Santos JM, Havunen R, Tähtinen S, Karell P, Sorsa S, Kanerva A, Hemminki A.

Oncoimmunology. 2018 Apr 9;7(5):e1412902. doi: 10.1080/2162402X.2017.1412902. eCollection 2018.

4.

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH.

JCI Insight. 2018 Apr 5;3(7). pii: 99573. doi: 10.1172/jci.insight.99573. eCollection 2018 Apr 5.

5.

Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients.

Taipale K, Tähtinen S, Havunen R, Koski A, Liikanen I, Pakarinen P, Koivisto-Korander R, Kankainen M, Joensuu T, Kanerva A, Hemminki A.

Oncotarget. 2018 Jan 5;9(5):6320-6335. doi: 10.18632/oncotarget.23967. eCollection 2018 Jan 19.

6.

A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma.

Capasso C, Magarkar A, Cervera-Carrascon V, Fusciello M, Feola S, Muller M, Garofalo M, Kuryk L, Tähtinen S, Pastore L, Bunker A, Cerullo V.

Oncoimmunology. 2017 May 11;6(9):e1319028. doi: 10.1080/2162402X.2017.1319028. eCollection 2017. Erratum in: Oncoimmunology. 2017 Oct 6;6(10 ):e1389146. Cervera-Carascon, Victor [corrected to Cervera-Carrascon, Victor].

7.

Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.

Santos JM, Havunen R, Siurala M, Cervera-Carrascon V, Tähtinen S, Sorsa S, Anttila M, Karell P, Kanerva A, Hemminki A.

Int J Cancer. 2017 Oct 1;141(7):1458-1468. doi: 10.1002/ijc.30839. Epub 2017 Jun 29.

8.

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.

Havunen R, Siurala M, Sorsa S, Grönberg-Vähä-Koskela S, Behr M, Tähtinen S, Santos JM, Karell P, Rusanen J, Nettelbeck DM, Ehrhardt A, Kanerva A, Hemminki A.

Mol Ther Oncolytics. 2016 Dec 31;4:77-86. doi: 10.1016/j.omto.2016.12.004. eCollection 2017 Mar 17.

9.

Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy.

Zafar S, Parviainen S, Siurala M, Hemminki O, Havunen R, Tähtinen S, Bramante S, Vassilev L, Wang H, Lieber A, Hemmi S, de Gruijl T, Kanerva A, Hemminki A.

Oncoimmunology. 2016 Dec 7;6(2):e1265717. doi: 10.1080/2162402X.2016.1265717. eCollection 2017.

10.

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models.

Hekim C, Ilander M, Yan J, Michaud E, Smykla R, Vähä-Koskela M, Savola P, Tähtinen S, Saikko L, Hemminki A, Kovanen PE, Porkka K, Lee FY, Mustjoki S.

Cancer Immunol Res. 2017 Feb;5(2):157-169. doi: 10.1158/2326-6066.CIR-16-0061-T. Epub 2017 Jan 10.

11.

Corrigendum to "Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma".

Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, Kanerva A, Hemminki A.

Mol Ther. 2016 Nov;24(11):2033. doi: 10.1038/mt.2016.196. No abstract available.

12.

T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.

Tähtinen S, Blattner C, Vähä-Koskela M, Saha D, Siurala M, Parviainen S, Utikal J, Kanerva A, Umansky V, Hemminki A.

J Immunother. 2016 Nov/Dec;39(9):343-354.

PMID:
27741089
13.

Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.

Siurala M, Vähä-Koskela M, Havunen R, Tähtinen S, Bramante S, Parviainen S, Mathis JM, Kanerva A, Hemminki A.

Oncoimmunology. 2016 Feb 18;5(5):e1136046. doi: 10.1080/2162402X.2015.1136046. eCollection 2016 May.

14.

Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer.

Liikanen I, Tähtinen S, Guse K, Gutmann T, Savola P, Oksanen M, Kanerva A, Hemminki A.

Mol Cancer Ther. 2016 Sep;15(9):2259-69. doi: 10.1158/1535-7163.MCT-15-0819. Epub 2016 Jul 25.

15.

Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.

Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, Kanerva A, Hemminki A.

Mol Ther. 2016 Aug;24(8):1435-43. doi: 10.1038/mt.2016.137. Epub 2016 Jun 30. Erratum in: Mol Ther. 2016 Nov;24(11):2033.

16.

Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.

Taipale K, Liikanen I, Juhila J, Turkki R, Tähtinen S, Kankainen M, Vassilev L, Ristimäki A, Koski A, Kanerva A, Diaconu I, Cerullo V, Vähä-Koskela M, Oksanen M, Linder N, Joensuu T, Lundin J, Hemminki A.

Mol Ther. 2016 Feb;24(1):175-83. doi: 10.1038/mt.2015.143. Epub 2015 Aug 27.

17.

Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors.

Tähtinen S, Kaikkonen S, Merisalo-Soikkeli M, Grönberg-Vähä-Koskela S, Kanerva A, Parviainen S, Vähä-Koskela M, Hemminki A.

PLoS One. 2015 Jun 24;10(6):e0131242. doi: 10.1371/journal.pone.0131242. eCollection 2015.

18.

Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.

Tähtinen S, Grönberg-Vähä-Koskela S, Lumen D, Merisalo-Soikkeli M, Siurala M, Airaksinen AJ, Vähä-Koskela M, Hemminki A.

Cancer Immunol Res. 2015 Aug;3(8):915-25. doi: 10.1158/2326-6066.CIR-14-0220-T. Epub 2015 May 14.

19.

Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy.

Vähä-Koskela M, Tähtinen S, Grönberg-Vähä-Koskela S, Taipale K, Saha D, Merisalo-Soikkeli M, Ahonen M, Rouvinen-Lagerström N, Hirvinen M, Veckman V, Matikainen S, Zhao F, Pakarinen P, Salo J, Kanerva A, Cerullo V, Hemminki A.

Mol Ther Oncolytics. 2015 Jan 7;1:14006. doi: 10.1038/mto.2014.6. eCollection 2015.

20.

Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.

Siurala M, Bramante S, Vassilev L, Hirvinen M, Parviainen S, Tähtinen S, Guse K, Cerullo V, Kanerva A, Kipar A, Vähä-Koskela M, Hemminki A.

Int J Cancer. 2015 Feb 15;136(4):945-54. doi: 10.1002/ijc.29048. Epub 2014 Jul 3.

21.

Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.

Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, Tähtinen S, Oksanen M, Heiskanen R, Pesonen S, Joensuu T, Alanko T, Partanen K, Laasonen L, Kairemo K, Pesonen S, Kangasniemi L, Hemminki A.

Clin Cancer Res. 2013 May 15;19(10):2734-44. doi: 10.1158/1078-0432.CCR-12-2546. Epub 2013 Mar 14.

22.

Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase.

Mattila E, Marttila H, Sahlberg N, Kohonen P, Tähtinen S, Halonen P, Perälä M, Ivaska J.

BMC Cancer. 2010 Jan 7;10:7. doi: 10.1186/1471-2407-10-7.

Supplemental Content

Loading ...
Support Center